VistaGen Therapeutics Inc (VTGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.24 (+2.74%), Market cap $0.02B, 52-week low–high $0.51 ~ $4.90.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor sy
Financial statements, price targets, institutional (13F) holdings and related news for VistaGen Therapeutics Inc are updated in real time on BlackAll Trade.
VistaGen Therapeutics Inc trades at $0.24 (+2.74%). Real-time quotes and charts are available on BlackAll Trade.
VistaGen Therapeutics Inc has a market cap of about $0.02B.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's pr